Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Hercessi (trastuzumab-strf)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eurofarma, Fosun Pharma, Intas

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (11)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

sunvozertinib (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

sevabertinib (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

diznalimgene lisbac (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

pertuzumab-dpzb (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + trastuzumab-strf Sensitive: C2 – Inclusion Criteria pertuzumab + trastuzumab-strf Sensitive : C2	pertuzumab + trastuzumab-strf Sensitive: C2 – Inclusion Criteria pertuzumab + trastuzumab-strf Sensitive : C2